IOVA

Business Context and Reporting Period

Company: IOVANCE BIOTHERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: February 20, 2024
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.

Key Financial Metrics

This filing details a capital raise rather than operational financial results. Key metrics related to the transaction include:

• Shares Issued: 23,014,000 shares of common stock.
• Offering Price: $9.15 per share.
• Price to Company: $8.601 per share (after underwriting discount).
• Estimated Net Proceeds: Approximately $197.1 million (after deducting underwriting discounts, commissions, and estimated offering expenses).
• Underwriters: Jefferies LLC, Barclays Capital Inc., and Goldman Sachs & Co. LLC.

Note: The filing text does not provide current revenue, profit, cash flow, margins, or debt levels. These operational metrics are not included in this specific 8-K report.

Material Changes and Transaction Details

The primary material change is the execution of an underwriting agreement to raise capital. The offering is expected to close on February 22, 2024, subject to customary closing conditions. Additionally, the Company's executive officers and directors have entered into 60-day "lock-up" agreements restricting the sale of their common stock, subject to certain exceptions.

Use of Proceeds and Outlook

Management intends to use the net proceeds from the offering for the following purposes:

• Support the commercial launch of AMTAGVI^TM.
• Fund ongoing clinical programs, specifically:
• The NSCLC registration-directed study (IOV-LUN-202).
• The frontline advanced melanoma Phase 3 confirmatory trial (TILVANCE-301).
• Continue the development of pipeline candidates.
• General corporate purposes.

Risks and Contingencies: The closing of the offering is subject to customary conditions. The Company has agreed to indemnify the underwriters against certain liabilities under the Securities Act.

Investor Verification Checklist

• Verify the final closing date of the offering (expected February 22, 2024) and the actual net proceeds received.
• Confirm the dilution impact of the 23,014,000 new shares on existing shareholders.
• Monitor the progress of the AMTAGVI^TM commercial launch and the specified clinical trials (IOV-LUN-202 and TILVANCE-301) funded by these proceeds.
• Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification clauses and lock-up exceptions.